Recent Updates in PEACE-3 Trial Presented at ESMO 2024

Opinion
Video

Panelists discuss how the EORTC-GUCG 1333 (PEACE-3) trial, presented at ESMO 2024, illuminates key findings regarding the study population and primary endpoints in genitourinary cancer research.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
1 expert is featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Evaluating Neoadjuvant and Adjuvant Therapies and Benefits for MIBC

Evaluating Neoadjuvant and Adjuvant Therapies and Benefits for MIBC

Targeted Oncology Staff
June 13th 2025
Article

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder cancer.

Read More

BCG Plus Mitomycin Shows Similar Efficacy, Fewer Doses in NMIBC

BCG Plus Mitomycin Shows Similar Efficacy, Fewer Doses in NMIBC

Silas Inman
June 2nd 2025
Article

The ANZUP 1301 trial showed that BCG and mitomycin showed similar DFS to BCG alone in NMIBC, but with 40% fewer BCG doses and similar safety.

Read More

FDA Clears IND for Novel Nectin-4 Targeted Radiopharmaceutical Across Cancers

FDA Clears IND for Novel Nectin-4 Targeted Radiopharmaceutical Across Cancers

Jordyn Sava
May 29th 2025
Article

A phase 1b trial plans to evaluate AKY-1189 for the treatment of Nectin-4–expressing tumors.

Read More

FDA ODAC Votes 5 to 4 Against UGN-102 for Recurrent LG-IR-NMIBC

FDA ODAC Votes 5 to 4 Against UGN-102 for Recurrent LG-IR-NMIBC

Jordyn Sava
May 21st 2025
Article

The FDA ODAC decided that the overall benefit-risk of the investigational therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk NMIBC.

Read More

First-Line Disitamab Vedotin/Toripalimab Shows Benefit in HER2+ la/mUC

First-Line Disitamab Vedotin/Toripalimab Shows Benefit in HER2+ la/mUC

Jordyn Sava
May 12th 2025
Article

Disitamab vedotin plus toripalimab showed significant survival benefits vs chemo in first-line HER2+ advanced urothelial carcinoma, with a manageable safety profile.

Read More

Durvalumab Plus BCG Improves Survival in Early Bladder Cancer

Durvalumab Plus BCG Improves Survival in Early Bladder Cancer

Jordyn Sava
May 9th 2025
Article

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the POTOMAC trial.

Read More